Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
-
UDIBI
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. VER MÁS
-
-
UDIBI
Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract (Transferon®). VER MÁS
-
UDIBI
Fecha de publicación: 20 de marzo del 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear...
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). VER MÁS
